Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MUCINEX DM vs GUAIFENESIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.
Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating expectoration.
Temporary relief of cough due to minor throat and bronchial irritation,Temporary relief of chest congestion and mucus buildup
Relief of productive cough associated with respiratory tract infections and common cold,Off-label: use as a muscle relaxant (unproven)
One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
Oral: 200-400 mg every 4 hours as needed, not to exceed 2400 mg/day.
Guaifenesin: 1-3 hours. Dextromethorphan: 3-30 hours depending on CYP2D6 phenotype; extensive metabolizers 3-8 hours, poor metabolizers 15-30 hours.
Terminal elimination half-life: 3-5 hours; clinical context: requires dosing every 4-6 hours for sustained mucolytic effect
Guaifenesin undergoes hepatic metabolism via oxidation and conjugation; dextromethorphan is metabolized by CYP2D6 to dextrorphan, an active metabolite.
Primarily hepatic via oxidation and demethylation; major metabolite is beta-(2-methoxyphenoxy)lactic acid. CYP450 enzymes not significantly involved.
Guaifenesin: renal (primarily as inactive metabolites, <1% unchanged). Dextromethorphan: renal (as unchanged drug and metabolites, including dextrorphan). Approximately 80% eliminated in urine as metabolites.
Renal: ~95% (primarily as unchanged drug and glucuronide conjugate); biliary/fecal: minimal (<5%)
Guaifenesin: approximately 30% to albumin. Dextromethorphan: approximately 50% to albumin and alpha-1-acid glycoprotein.
~50% (bound to albumin)
Guaifenesin: 0.8-1.5 L/kg. Dextromethorphan: 5-10 L/kg (extensive tissue binding).
~1 L/kg; clinical meaning: extensive distribution into extravascular tissues, including respiratory secretions
Oral: Guaifenesin ~100% (tablet/syrup). Dextromethorphan ~11% (extensive first-pass metabolism; varies with CYP2D6 phenotype).
Oral: 80-85% (first-pass metabolism minimal)
Cr Cl 30-50 m L/min: administer every 24 hours. Cr Cl <30 m L/min: not recommended. Hemodialysis: not recommended. Peritoneal dialysis: not recommended.
No specific guidelines; use caution in severe impairment due to potential accumulation of metabolites.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or extend interval to every 24 hours. Child-Pugh C: not recommended.
No adjustment required for mild to moderate impairment; insufficient data for severe impairment.
Children ≥12 years: same as adult. Children 6-11 years: guaifenesin 300 mg / dextromethorphan 15 mg orally every 12 hours, not to exceed 2 doses in 24 hours. Children <6 years: not recommended.
Children 2-5 years: 50-100 mg every 4 hours, max 600 mg/day; 6-11 years: 100-200 mg every 4 hours, max 1200 mg/day; ≥12 years: same as adult.
Start at lower end of dosing range (e.g., one tablet every 24 hours) due to age-related renal and hepatic decline; monitor for CNS effects and constipation.
No specific adjustment; use lowest effective dose due to increased sensitivity and risk of adverse effects.
None
None
Do not use for persistent/chronic cough, cough with excessive phlegm, or cough due to smoking/asthma/COPD/emphysema,Serotonin syndrome risk with MAOIs or other serotonergic drugs,Dextromethorphan abuse potential,Hypersensitivity reactions
Use with caution in patients with persistent or chronic cough (e.g., smoking, asthma, COPD); if cough persists >7 days or recurs, or with fever/rash/headache, discontinue and evaluate.
Concomitant use with MAOIs or within 14 days of MAOI therapy,Hypersensitivity to any component
Hypersensitivity to guaifenesin or any component of the formulation.
No significant food-drug interactions. However, alcohol may potentiate CNS effects (drowsiness/dizziness) and should be avoided.
No significant food interactions. Alcohol may exacerbate CNS depressant effects.
FDA Category C for guaifenesin and dextromethorphan. First trimester: limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks at recommended doses. Avoid high doses of dextromethorphan due to potential serotonin reuptake inhibition and theoretical risk of fetal serotonin syndrome.
Insufficient human data; animal studies show no evidence of fetal harm. Generally considered low risk across all trimesters, though use in first trimester should be cautious due to lack of robust data.
Guaifenesin: excreted into breast milk in small amounts; no known adverse effects in infants at maternal therapeutic doses. Dextromethorphan: likely excreted into breast milk in low concentrations; M/P ratio not established. Use caution; monitor infant for sedation, respiratory depression, or constipation.
Excretion into breast milk is likely minimal; M/P ratio not established. AAP considers compatible with breastfeeding; avoid excessive doses.
No dose adjustment required for guaifenesin or dextromethorphan during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased renal clearance) are not clinically significant at standard doses. Use the lowest effective dose for the shortest duration.
No dosage adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) are not clinically significant for guaifenesin.
Mucinex DM combines guaifenesin (expectorant) and dextromethorphan (antitussive). Guaifenesin is best taken with adequate fluid intake to thin mucus. Dextromethorphan is contraindicated with MAOIs and in patients with serotonin syndrome risk. Avoid use in patients with chronic cough due to smoking, asthma, or COPD without physician guidance.
Guaifenesin is an expectorant that increases respiratory tract fluid to reduce mucus viscosity. Onset of action is about 30 minutes; duration is 4-6 hours. Maximum effect requires adequate hydration. Avoid in persistent cough due to smoking, asthma, or emphysema. Use caution in renal impairment (Cr Cl <30 m L/min). Not recommended for children under 6 years without medical advice.
Take with a full glass of water to help loosen phlegm.,Do not crush or chew extended-release tablets; swallow whole.,Avoid driving or operating machinery if drowsy or dizzy.,Do not use with other cough/cold medications containing dextromethorphan.,Stop use and consult doctor if cough persists >7 days or with fever, rash, or headache.
Drink plenty of water while taking this medication to help loosen mucus.,Do not take for more than 7 days unless directed by a doctor.,Stop use and consult a doctor if cough persists for more than 7 days, is accompanied by fever, rash, or persistent headache.,Avoid alcohol as it may increase dizziness or drowsiness.,Do not crush or chew extended-release tablets; swallow whole.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MUCINEX DM vs GUAIFENESIN, answered by our medical review team.
MUCINEX DM is a Expectorant/Antitussive Combination that works by Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.. GUAIFENESIN is a Expectorant that works by Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating expectoration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MUCINEX DM and GUAIFENESIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MUCINEX DM is: One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.. The standard adult dose of GUAIFENESIN is: Oral: 200-400 mg every 4 hours as needed, not to exceed 2400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MUCINEX DM and GUAIFENESIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MUCINEX DM is classified as Category C. FDA Category C for guaifenesin and dextromethorphan. First trimester: limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and. GUAIFENESIN is classified as Category C. Insufficient human data; animal studies show no evidence of fetal harm. Generally considered low risk across all trimesters, though use in first trimester should be cautious due to. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.